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Aurélien Mazeraud1,2†, Andrea Polito1,3,4† and Djillali Annane3,4*†Abstract
Stress-induced hyperglycemia has been considered an
adaptive mechanism to stress up to the first intensive
insulin therapy trial, which showed a 34% reduction in
relative risk of in-hospital mortality when normalizing
blood glucose levels. Further trials had conflicting results
and, at present, stress-induced hyperglycemia management
remains non-consensual. These findings could be
explained by discrepancies in trials, notably regarding
the approach to treat hyperglycemia: high versus
restrictive caloric intake. Stress-induced hyperglycemia is
a frequent complication during intensive care unit stay
and is associated with a higher mortality. It results from
an imbalance between insulin and counter-regulatory
hormones, increased neoglucogenesis, and the
cytokine-induced insulin-resistant state of tissues. In this
review, we summarize detrimental effects of
hyperglycemia on organs in the critically ill (peripheric
and central nervous, liver, immune system, kidney, and
cardiovascular system). Finally, we show clinical and
experimental evidence of potential benefits from
glucose and insulin administration, notably on
metabolism, immunity, and the cardiovascular system.viving Using Glucose Algorithm Regulation), which sug-Introduction
In an ICU, stress induces insulin resistance and overpro-
duction of glucose, resulting in a syndrome called stress-
induced hyperglycemia (SIH) [1]. SIH is common during
critical illness and is associated with high mortality
[1-3]. Its incidence is approximately 50% in septic shock* Correspondence: djillali.annane@rpc.aphp.fr
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2014[1] and 13% in surgical patients [4]. Up to the beginning
of the 21st century, hyperglycemia was considered an
adaptive mechanism to stress. In 2001, the landmark
Leuven study by Van den Berghe and colleagues [4] re-
ported a 34% relative risk reduction of in-hospital mor-
tality when blood glucose was maintained at between 80
and 110 mg/dL. Since then, glucose metabolism during
critical illness has been the focus of an increasing num-
ber of experimental and clinical studies. A decade later,
after seven additional major randomized control trials,
physicians remain confused about how to manage SIH.
The heterogeneity of studies includes differences in
population, ICU setting, staff experience, feeding strat-
egy, blood glucose monitoring, variability, definition of
hypoglycemia, insulin protocol, infusion site, its continu-
ation after ICU discharge, and finally differences in the
choice of the relevant major outcome. In the two ‘posi-
tive’ trials from Leuven, mean non-protein daily caloric
intake was approximately 20 kcal/kg per day, essentially
via glucose administration initially given intravenously:
up to 200 to 300 g/day in the 2001 trial, with a median
total daily insulin administration of 71 units (confidence
interval of 48 to 100). By contrast, in NICE-SUGAR
(Normoglycemia in Intensive Care Evaluation and Sur-
gested increased mortality with intensive insulin therapy,
caloric intake was 11.04 ± 6.08 kcal/kg per day, with
19.5% given intravenously, and cumulative mean daily
dose of insulin was 50.2 ± 38.1 units per day [5]. Thus,
there were two markedly different therapeutic ap-
proaches - that is, intensive gluco- and insulin therapy
(liberal glucose intake, or the Leuven approach) and in-
tensive insulin therapy (IIT) (restrictive glucose intake,
or the NICE-SUGAR approach) [6]. The aim of this re-
view is to discuss experimental evidence of organ injury
and insulin sensitivity during SIH and expose differences
in strategies for its control that include a liberal or a ra-
ther restrictive glucose intake.ral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
is properly cited. The Creative Commons Public Domain Dedication waiver
/zero/1.0/) applies to the data made available in this article, unless otherwise
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After several large clinical trials, there is still no consen-
sus on what blood glucose level (BGL) is ‘too much’.
Whereas the Leuven trial demonstrated deleterious ef-
fects from uncontrolled glucose levels, subsequent trials
comparing strategies to control BGL reported conflicting
results [4,5,7-11].
SIH is undoubtedly associated with mortality in stroke
[12], brain injury [2], and myocardial infarction [13] pa-
tients; trauma, cardiothoracic surgery, thermally injured,
and mixed ICU patients [3]; and non-ICU hospitalized
patients. The aim of this section is to summarize current
knowledge about the mechanisms of hyperglycemia
toxicity.Pathogenesis of stress-induced hyperglycemia
Critical illness is characterized by an imbalance between
insulin and endogenous or exogenous counter-
regulatory hormones (glucagon and glucocorticoids). As
a result, glucose production is increased and its storage
is decreased secondary to downregulated glycogen syn-
thesis and enhanced glycogenolysis [1]. In animal
models, adrenaline infusion induces hyperglycemia via
stimulation of hepatic and renal neoglucogenesis [14].
This pathway represents the major source of endogen-
ous glucose during critical illness [1].
SIH is also the consequence of insulin resistance [1].
Experimental data on the mechanisms of sepsis-induced
acute insulin resistance are scarce. Most of the know-
ledge about the mechanisms of acute insulin resistance
comes from trauma/hemorrhage experimental models
and studies in type 2 diabetes [15]. Under healthy condi-
tions, insulin binding to its receptor results in the phos-
phorylation of insulin receptor substrates, which
transmit insulin metabolic and growth signals. One
major effector of the metabolic pathway is glucose trans-
porter family (GLUT) 4, which facilitates glucose trans-
port across cell membranes in muscle and adipose
tissue. During injury, inhibitor of kappa B kinase and
Jun B pathways are activated, leading to expression of in-
flammatory markers such as TNF. First, Jun B negatively
regulates insulin receptor substrate and then TNF down-
regulates GLUT 4 gene transcription [16]. These mecha-
nisms could account for insulin resistance during sepsis
[17].
Whether this mechanism of response to aggression is
deleterious during critical illness is still a matter of de-
bate [18]. In fact, insulin resistance is variable from one
tissue to another and appears to be moderate in the
heart and diaphragm but is major in skeletal muscles
and adipocytes [19]. In fact, despite this insulin resist-
ance, glucose utilization is enhanced in sepsis secondary
to different GLUT overexpression [20].Glucose transport across cell membranes is the rate-
limiting step of cellular glucose metabolism. Each GLUT
is characterized mostly by organ specificity, insulin sen-
sitivity, and the Michaelis constant (Km). Km is defined
as the transporter’s specific value of glycemia for which
50% of transport capacities are reached. These character-
istics (Table 1) could explain differences in organ sensi-
tivity to insulin and modulation of glucose uptake with
glycemia. This heterogeneity may be seen as a protective
effect of vital organs while placing other organs in a ‘hi-
bernating state’.
Hyperglycemia is responsible for reactive oxygen spe-
cies (ROS) overproduction in diabetes via four major
pathways: advanced glycated endproduct release, de novo
indirect activation of C kinase protein, increased polyol,
and hexosamine pathway flux redox homeostasis [21].
On one hand, some ROS production can be essential for
immune cell ‘respiratory burst’ to kill pathogens or for
endothelial cell functions. On the other hand, during
hyperglycemia, excess ROS may worsen organ failure
[22].
Hyperglycemia and the central nervous system
Brain cells are dependent on glucose to maintain their
membrane ionic gradient. However, the detrimental
cerebral effects of hyperglycemia have been observed in
critical illness [2,12,23].
Brain glucose metabolism has some particularities:
 Glucose crosses blood–brain barrier and cellular
membranes via a high-affinity and insulin-insensitive
process involving GLUT 1 and GLUT 3 [24].
 Neurons and astrocytes cooperate to metabolize
carbohydrates, as suggested by lactate shuttles
between these cells.
 During hypoxemic or hypoperfusion stress, GLUT 1
and 3 are upregulated (up to 300% in trauma) with a
subsequent increase in glucose uptake [25].
Hyperglycemia has been shown to enhance the break-
down of the blood–brain barrier via induction of matrix
metalloproteinase [26] and to induce apoptosis [23],
mostly via enhanced superoxide production. Indeed, in
epidemiologic studies on stroke, hyperglycemia is associ-
ated with edema, infarct size, mortality in non-diabetic
patients, and poor functional status at 1 year [12].
Nevertheless, trials aiming at controlling BGL in stroke,
subarachnoid hemorrhage [27], brain injury [28], and
neuro-intensive care [29] patients did not report im-
proved outcome with tight glucose control.
Hyperglycemia and the peripheral nervous system
Neuromyopathy is a frequent complication of critical ill-
ness, such as septic shock and acute respiratory distress






GLUT 4 Yes Muscle, adipocytes 460 Accounts for insulin resistance. Glycemia-dependent transporter
GLUT 1 No Blood–brain barrier, astrocytes,
cardiomyocytes, liver, endothelium
25 Rate-limiting step of glucose transport in brain. Upregulated
up to 1.7-fold in sepsis
GLUT 2 No Liver, kidney, beta pancreatic cells 300 Glycemia-dependent transport
GLUT 3 No Brain 25 Second important transporter in brain
GLUT, glucose transporter.
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with these conditions. In the first Leuven study, the risk
of developing a critical illness neuromyopathy (CINM)
was lowered from 49% to 25% (P < 0.0001) in the inter-
ventional group, facilitating weaning from mechanical
ventilation. The mechanisms of hyperglycemic neuro-
myopathy are poorly understood and may involve activa-
tion of apoptotic and inflammation pathways in
response to acute hyperglycemia in muscles [30] or ROS
overproduction as suggested in type 2 diabetic neur-
opathy or CINM pathogenesis [21].
Hyperglycemia and other organs
Liver
In resting conditions, GLUT 2 is the predominant trans-
porter for glucose in hepatic parenchymal cells [24,31].
This low-affinity transporter modulates glucose trans-
port proportionally to BGL. After lipopolysaccharide
(LPS) stimulation, GLUT 2 decreases, whereas GLUT 1
increases [31], resulting in an enhanced insulin- and
glycemia-independent uptake of up to 2.4-fold [31,32].
Analyses of liver cells from the control group of the Leu-
ven study revealed dramatic lesions to the mitochondria.
These mitochondria abnormalities may result from ex-
cessive glucose uptake, with subsequent overproduction
of ROS [33], which could have been diminished with
BGL normalization.
Immune system
In the Leuven study, patients with normoglycemia had
almost 50% fewer bloodstream infections (7.8% versus
4.2%, P = 0.003) [4]. Indeed, each step of the immune re-
sponse to stress is altered with hyperglycemia. First, in
diabetes, chronic high BGL induces overexpression of
surface and circulating cell adhesion molecules [34-36],
whereas LPS challenge is less effective in upregulating
cell adhesion molecules [34]. This enhanced overall im-
mune cell adhesion paradoxically results in a less effect-
ive chemotactism and transmigration capacity of
immune cells [37]. Second, worse polymorphonuclear
killing capacities against pathogens, as assessed by con-
centrations of lysosomal enzyme or burst respiratory in-
tensity, are observed when BGL is poorly controlled
with a dose-effect relationship in diabetes [38]. Finally,the production of chemokines and other pro-
inflammatory factors is decreased under hyperglycemic
conditions [39].Kidney
In septic shock, GLUT 2 and 3 expressions are de-
creased in the tubular epithelial cells of the kidney,
whereas GLUT 1 expression is increased. This may ac-
count for enhanced glycosuria and acute renal failure
during septic shock [40]. In the Leuven study, renal re-
placement therapy was twice less frequent in patients
with normoglycemia, whereas insulin per se was associ-
ated with worse renal outcome [41]. This kidney protec-
tion may result directly from lower BGL, since high BGL
directly inhibits transcription of an anti-apoptotic gene
in renal tubules [42] or from improvement in lipid pro-
file, ROS production, and endothelial protection [43].Heart and endothelium
SIH has been shown to be an important prognostic fac-
tor in acute coronary syndromes [13]. The heart has a
remarkable ability to switch from free fatty acid oxida-
tion to carbohydrate oxidation under hypoxemic condi-
tions [44]. During acute myocardial infarction, SIH
activates T cells in the atherosclerotic plaque and in-
creases tissue levels of inflammatory markers and nitric
oxide and ROS production, resulting in endothelial dys-
function [45]. Consequently, coronary blood flow and re-
serve during myocardial infarction are impaired [46].
Furthermore, acute hyperglycemia increases infarct size
and suppresses cardioprotective signal transduction via
mitochondrial potassium ATP channel inhibition [47].
In shock, although BGLs are high, glucose represents
only 12% of substrate oxidation by cardiomyocytes [48].
Therefore, one could argue that hyperglycemia without
insulin infusion does not confer a metabolic benefit and
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In the Leuven studies, patients were given intravenous
glucose at 8 to 12 g/hour, with mean intravenous glucose
feeding of 120 g during the first 15 hours, to a goal of
200 to 260 g/day afterward. This study shows higher
intravenous glucose and insulin administration than in
any other study (Table 3), whereas epidemiologic studies
have shown that both are correlated with an increased
mortality [3,41,52].
Other trials of glucose control in the ICU used lower
glucose intake and insulin doses. In none of these stud-
ies did the experimental intervention achieve mainten-
ance of normal BGL like in the Leuven study. NICE-
SUGAR is the only study showing increased mortality
with tight BGL control. In that study, total caloric intake
was much lower than in the Leuven study. In the Spe-
cialized Relative Insulin and Nutrition Tables (SPRINT)
study, a 35% lowering of hospital mortality for patients
with a long stay in the ICU (P = 0.02) was observed after
implementation of tight glucose control when glucose
was administered enterally to allow a caloric intake of
25 kcal/kg per day. Likewise, the cumulative insulin dose
per day was close to that observed in the experimental
group of the Leuven study (67.2 units in SPRINT versus
71 units). These findings are in line with the latest IIT
meta-analysis by Marik and Preiser [6], who suggestedTable 2 Trials’ calendar
Year Trial
2001 The first Leuven RCT (1,548 patients) reported a 34% relative risk reduc
110 mg/dL [4].
2003 Krinsley [49], in an observational study (1,826 patients), confirmed the
than 140 mg/dL.
2006 The second Leuven RCT (1,200 patients) confirmed a 10% absolute red
maintenance of BGL of between 80 and 110 mg/dL [11].
2008 De la Rosa et al. [9] RCT (504 patients) failed to show any survival ben
with less effective control.
The VISEP study, with the same glycemic goals (537 patients with sep
incidence of hypoglycemia (17.0% versus 4.1%; P < 0.001) and no evid
Arabi et al. [8] RCT (523 patients) also failed to show survival benefit (a
showed increased hypoglycemic rates (28.6% versus 3.1% of patients;
SPRINT (BGL goal of 72 to 110 mg/dL) is an observational study with h
and tighter glucose control (standard deviation of blood glucose was
improvement in organ failures and outcome for long-stay ICU patient
P < 0.0001) [51].
2009 The Glucontrol (1,101 patients) was stopped prematurely for unintend
hypoglycemia (8.7% versus 2.7%; P = 0.0001) and a non-significant tren
controlled [10].
2009 The NICE-SUGAR trial (6,104 mixed ICU patients) compared a strategy
egy (<180 mg/dL). This RCT found an increase in mortality with IIT (27
versus 0.5%; P < 0.001) [7].
2010 COITTSS (509 patients with septic shock) compared a strategy of BGL
less than 150 mg/dL. This trial did not find any difference in in-hospita
BGL, blood glucose level; COITTSS, Corticosteroids and Intensive Insulin Therapy for
Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation; RCT, r
Tables; VISEP, Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis.that intravenous calorie administration plays a pivotal
role for improvement of outcome during IIT. In con-
trast, the last Leuven trial, EPaNIC (Early versus late
Parenteral Nutrition in Intensive Care), showed that par-
enteral nutrition administration to achieve a caloric in-
take of 20 to 25 kcal/kg per day might be detrimental.
This raises the question of the effect of an exclusive and
important glucose infusion during IIT in critical illness.
It was then suggested that, in the Leuven trial, differ-
ence in observed mortality was secondary to a higher
mortality in the control group due to an excessive glu-
cose load. Nevertheless, control mortality in the Leuven
study matched the mortality expected from estimation
of the EuroSCORE (European System for Cardiac Op-
erative Risk Evaluation). Secondly, a recent meta-analysis
suggested that intravenous glucose intake was an inde-
pendent predictive factor for good outcome in the
Leuven studies [6]. But whether blood glucose control
or insulin administration mediated positive effects in this
study was not studied.
In 2003, Van den Berghe and colleagues [41] per-
formed a post-hoc analysis of their first study. The au-
thors showed that both total amount of infused insulin
and glycemic control were associated with lower mortal-
ity (independently of age, delayed ICU admission, Acute
Physiology and Chronic Health Evaluation II score,tion in hospital mortality with maintenance of BGL of between 80 and
survival benefit associated with protocolized IIT targeting a BGL of less
uction in hospital mortality for long-stay medical ICU patients with
efit in mixed ICU patients targeting BGL between 80 and 110 mg/dL but
tic shock), was terminated prematurely because of an unacceptably high
ence for survival benefit at 90 days (39.7% versus 35.4%; P = 0.31) [50].
djusted hazard ratio 1.09, 95% confidence interval 0.70 to 1.72) and
P < 0.0001).
istoric control. Nutritional and insulin protocols provided less variable
38% lower compared with the retrospective control) with subsequent
s: failure-free days were different (SPRINT = 41.6%; Pre-SPRINT = 36.5%;
ed protocol violations. The IIT was associated with increased
d to higher mortality (15.3% versus 17.2%) while BGL was not optimally
of BGL control of between 81 and 108 mg/dL versus a more liberal strat-
.5 versus 24.9; P = 0.02) and increased incidence of hypoglycemia (6.8%
control of between 80 and 110 mg/dL versus maintenance of BGL of
l mortality between the two strategies (45.9% versus 42.9%; P = 0.05) [8].
Septic Shock; IIT, intensive insulin therapy; NICE-SUGAR, Normoglycemia in
andomized controlled trial; SPRINT, Specialized Relative Insulin and Nutrition
Table 3 Summary of characteristics from the different major trials about glucose-insulin treatment
Study name VDB 2001 [4] VDB 2006 [11] Glucontrol [10] NICE-SUGAR [5] COITTSS [7] VISEP [50]
Experimental Control Experimental Control Experimental Control Experimental Control Experimental Control Experimental Control
Morning mean BGL, mg/dL 103.6 154.5 110.0 160.9 110.9 140.0 118.0 144.9 147.3 154.5 112.7 152.7
SD or confidence interval 20.0 32.7 30.0 28.0 100-123.6 121.8- 160 25.1 26.0 30.9 34.5 1.8 3.6
Death at 90 days, % 5 7 35.9 37.7 23.3 19.4 27.5 24.9 45.9 42.9 39.7 35.4
Caloric intake, kcal/day 550-1,600 1,202 1,237 760 760 891 872 1,350 1,217 1,253
Quantity of glucose administered per day, g 120 202 198 73.7 71.8 23.4 24.4 25 144 144
Daily insulin dose, insulin units 71 33 59 10 31.2 7.68 50.2 16.9 71 46 43 29
SD or confidence interval 48-100 17-56 37-86 0-38 15.6- 55.2 30.48 38.1 29 45-96 30-65 23-64 15-51
Hypoglycemia rate, % 0.8 5 18.7 3.1 8.7 2.7 6.8 0.5 16.4 7.8 10.1 4.1
BGL, blood glucose level; COITTSS, Corticosteroids and Intensive Insulin Therapy for Septic Shock; NICE-SUGAR, Normoglycemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm Regulation; SD, stand-
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betes, and at-admission hyperglycemia). The strength of
association between the mortality rate and the mean
BGL seemed to be stronger than with the total daily in-
fused insulin [41]. Nevertheless, no statistical compari-
son was made between these factors in this study.
Furthermore, the respective effects of these two
entwined factors could be analyzed only in an interven-
tional study comparing gluco-insulinotherapy versus
tight glycemic control. Then a recent study by Arabi and
colleagues [53] with a 2 × 2 factorial design compared
IIT and permissive underfeeding (60% to 70% of daily
recommended caloric intake versus 90% to 100%). Their
study showed no mortality differences between groups
but was underpowered and non-blinded, and the thera-
peutic goals were not achieved [53].
Finally, in 2011, the Leuven group performed the EPa-
NIC study that evaluated the timing of parenteral nutri-
tion introduction. In that study, a strategy of early
parenteral nutrition initiation was performed with ad-
ministration of 400 kcal (100 g) at day 1 and 800 kcal at
day 2 exclusively via intravenous glucose administration,
and then a relay with mixed parenteral and enteral nu-
trition was performed to achieve calculated daily physio-
logical caloric intake [54]. The control group received
minimal glucose administration and enteral nutrition
was started at day 2 if oral intake was insufficient. Re-
sults showed an increased rate of complications in the
parenteral nutrition group (infection and cholestasis),
whereas the late initiation of parenteral nutrition re-
sulted in a shorter duration of renal replacement ther-
apy, mechanical ventilation, and stay in the ICU. In that
study, the amount of administered glucose was three
times lower than in the 2001 study, and insulin doses
were also lower in both groups: 31 insulin units (inter-
quartile range (IQR) 19 to 48) in the control versus 58
insulin units (IQR 40 to 85) in the experimental group.
Furthermore, parenteral nutrition contains lipid at rec-
ommended doses that could present detrimental effects
as fat oxidation is a high oxygen-consuming metabolic
pathway. A post-hoc analysis of EPaNIC concerning the
first 2 days in the ICU in that study before introduction
of parenteral nutrition might be of interest to clinicians
and help them determine whether high glucose adminis-
tration during IIT is beneficial for patients. We will
present clinical and experimental evidence that may sup-
port the use of a glucose-insulin administration strategy.
Is gluco-insulinotherapy associated with a decreased
incidence of hypoglycemia?
The clinical signs of hypoglycemia are commonly
masked in sedated patients. Thus, in clinical trials,
hypoglycemia was defined empirically by a BGL value of
less than 40 mg/dL. Its incidence varied from 5.1% to18.7% in patients with IIT and from 0.5% to 4.1% in con-
trol groups. Seizures and comas have occasionally been
observed following severe hypoglycemic episodes with-
out establishing a clear causal relationship [55]. Neur-
onal death during or following hypoglycemia has also
been found in both animal and human models, but
hypoglycemia does not seem to affect neurocognitive de-
velopment in children [56] but may contribute to long-
term cognitive impairment following critical illness in
adults [57]. The existence of a direct causal link between
hypoglycemia and mortality remains controversial, and
hypoglycemia could reflect only a more severe illness.
Some epidemiologic studies have found that only early
or spontaneous hypoglycemia was independently associ-
ated with death in critically ill patients [58,59]. Prevent-
ive interventions are thus warranted in such a situation.
Whether an increased daily amount of carbohydrate ad-
ministered would decrease the risk of hypoglycermia
during tight BGL is unknown.
In a retrospective study by Arabi and colleagues [60],
glucose intake was not a risk or protective factor of
hypoglycemia whereas insulin daily dosage was an evi-
dent risk factor (73.5 ± 36.7 in the group presenting
hypoglycemia versus 47.5 ± 51.8; P < 0.0001) [60]. Actu-
ally, caloric intake lowering (gastroparesis, intravenous
glucose, or enteral nutrition lowering) without insulin
adjustment may be one of the most frequent risk factors
for hypoglycemia [54,55,60,61], and no study evaluated
the effect of gluco-insulinotherapy on hypoglycemia rate.
The recent EPaNIC study showed a decreased rate of
hypoglycemia during IIT when early parenteral nutrition
was initiated (1.9% versus 3.5%, P = 0.001), suggesting a
possible protective role of gluco-insulinotherapy to be
explored in an interventional study [54].
Effects of high insulin and glucose intake on organs
Gluco-insulinotherapy consists of a high amount of glu-
cose infused and higher insulinemia. Effects of insulin
on glycemia lowering are mediated mostly by an increase
in cellular uptake of glucose through GLUT 4 transloca-
tion to the membrane. GLUT 4 is located mostly on adi-
pocytes and skeletal muscle cells [1]. Thus, mostly
GLUT 4-expressing cells consume glucose administered
intravenously during IIT.
During early sepsis, metabolic stress resulted in glyco-
genolysis and depleted energetic reserves as shown in
skeletal muscle biopsies [33,62]. This ATP depletion was
correlated with poor outcome, and in addition recovery
from sepsis was preceded by normalization of the
phosphocreatine/ATP ratio [62]. Indeed, energy deple-
tion during sepsis could be a risk factor for CINM, an
ICU complication associated with higher mortality [63].
In fact, skeletal muscle protein levels were higher in the
IIT group consistently with anabolic effects of insulin
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in adipose and skeletal muscle cells and the glucose up-
take by myocytes [64]. This higher amount of energetic
substrate may be a protective factor against energy de-
pletion and sarcopenia and may lower the risk to de-
velop CINM. These findings are in line with the
observed lower rate of CINM and the late improvement
in survival in the Leuven trials [4,11].
Experiments from the Leuven cohort showed that
maintenance of normal BGL protected the liver and
skeletal muscles. In the liver, glucose uptake through
GLUT 2 is independent of BGLs. Indeed, untreated
hyperglycemia was associated with severely damaged
mitochondria with altered complex I and IV activities
[33]. Furthermore, insulin administration during injury
partly suppresses gluconeogenesis [65]. Gluconeogenesis
is an active process occurring mostly in the liver that re-
quires four molecules of ATP and two molecules of
GTP. This energy requirement may enhance hypoxic in-
jury in liver during stress and could be counteracted
with insulin administration [64-66].
Whether gluco-insulinotherapy rather than BGL con-
trol protects the liver from hypoxic injury has been stud-
ied in few human and experimental studies. One study
conducted by a different group showed beneficial effects
of insulin independently of BGLs on hepatocyte apop-
tosis, cytolysis, and expression of inflammatory markers
[65]. Further studies in the Leuven group did not repro-
duce these results and showed a lower blood level of
transaminases in burn-injured rabbits with BGL control
rather than insulin administration [67]. Liver injury may
be mediated by a mitochondriopathy in reaction to cel-
lular hyperglycemia and enhanced glycolysis and is likely
to mediate organ damage [68]. As insulin sensitivity is
not overcome during IIT in the liver, glucose uptake by
hepatocytes is likely to be dependent on glycemia rather
than insulinemia [66].
In sepsis models, insulin has been shown to improve
immune cell function independently of glycemia. It in-
hibits the apoptosis of activated macrophages, may
modulate antigen presentation, and improves chemo-
taxis and phagocytic properties. Finally, insulin may
modulate the balance between lymphocyte T helper type
and lymphocyte T helper type 2 cells, favoring anti-
inflammation and repair function [69]. Such effects of
insulin on the immune system may account for the re-
duced rate of bloodstream infection during IIT [4].
During sepsis, the heart shows little or no insulin re-
sistance [70] and lowers its glucose consumption
[48,70]. In porcine models, glucose and insulin infusion
favored glucose and lactate utilization. This results in
improvement in inotropic function without higher oxy-
gen consumption observed in different studies [67,71].
In fact, during acute coronary syndrome, glucose insulinpotassium therapy was associated with substantial sur-
vival and may prevent arrhythmias [72]. However, the
benefit of glucose insulin potassium infusion in patients
with myocardial infarction remains controversial. In the
ICU, IIT was not associated with reduced time or doses
of inotropic support [4] and was associated with a higher
incidence of cardiovascular death in NICE-SUGAR [5],
but the Leuven study introduced IIT with an important
amount of intravenous glucose administered to cardio-
vascular post-surgical patients. Such an inotropic effect
may have improved organ perfusion and contributed to
the lower renal failure rate and the better outcome in
these patients.
In summary, gluco-insulinotherapy may present protect-
ive effects on muscle or improve immune or cardiac func-
tion. Contrary to Marik and Bellomo [18] in their recent
comment, we hypothesize that gluco-insulinotherapy may
be a more beneficial rather than a restrictive strategy. This
issue needs to be further studied.
Conclusions
The era of glucose control in the ICU started in 2001.
Untreated SIH no doubt favors morbidity and mortality.
Critical analyses of randomized controlled trials have
suggested that glucose control is more likely to be asso-
ciated with survival benefit when strict normal glucose
levels are achieved and early high glucose intake is pro-
vided. An interventional study evaluating liberal and re-
strictive glucose intake during IIT is warranted to
provide reliable evidence.
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